Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report
Open Forum Infectious Diseases · 23.12.2024 · 12 (1)
DOI: 10.1093/ofid/ofae705 ↗Kurz gefasst
Fallbericht in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 29.11.2024. Verfasst von Jeroen J A van Kampen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Viroscience Department, Erasmus MC, Rotterdam, The Netherlands. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Dutch Aidsfonds, Canadian Institutes for Health Research.
Abstract (Originalsprache)
Background
The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer inhibitors, particularly dolutegravir, have improved treatment outcomes for people with HIV-2. Lenacapavir, a novel and potent antiretroviral capsid inhibitor, offers additional therapeutic options. However, limited knowledge exists regarding HIV-2 resistance against dolutegravir and lenacapavir.
Methods
We report the case of a treatment-experienced individual who did not achieve virological suppression with regimens containing dolutegravir and lenacapavir. Clinical monitoring, genotypic and phenotypic resistance assays, and in silico structural modeling were performed.
Results
Lenacapavir was added to a failing regimen of boosted darunavir, twice daily dolutegravir, and 2 nucleoside reverse transcriptase inhibitors. Initially, this addition led to a decline in the viral load and increase in CD4+ T-cell count, despite the identification of a previously unreported combination of integrase resistance mutations. However, virological suppression was not achieved and viral load, although reduced, resumed increasing. This rebound was associated with the development of an N73D capsid substitution in HIV-2, which conferred resistance against lenacapavir. Based on cell-based assays predicting hypersusceptibility to bictegravir, the regimen was adjusted to oral lenacapavir plus bictegravir/emtricitabine/tenofovir alafenamide, resulting in a resumption in viral load decline.
Conclusions
Although lenacapavir demonstrated therapeutic potential, our case underscores the critical need to combine it with other fully active antiretroviral agents to prevent the rapid emergence of resistance and achieve long-term virological control in treatment-experienced individuals with HIV-2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
- Department of Medical Microbiology & Infectious Diseases and Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
- Service de Virologie, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Université Paris Cité, Paris, France.
ORCID-Profile: Jeroen J A van Kampen, Els van Nood, Zoë Krullaars, Tess Nijssen, Jolanda J C Voermans, Quentin Le Hingrat, David A M C van de Vijver, Rob A Gruters, Thibault Mesplède
Förderung
- NIAID NIH HHS
- Dutch Aidsfonds
- Canadian Institutes for Health Research
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
van Kampen, J. J. A., van Nood, E., Mahmud, R., Krullaars, Z., Voskamp, T., Voskamp, M., Nijssen, T., Voermans, J. J. C., Charpentier, C., Le Hingrat, Q., van de Vijver, D. A. M. C., Gruters, R. A., & Mesplède, T. (2024). Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report. Open Forum Infectious Diseases, 12(1). https://doi.org/10.1093/ofid/ofae705
Vancouver
van Kampen JJA, van Nood E, Mahmud R, Krullaars Z, Voskamp T, Voskamp M, et al. Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report. Open Forum Infectious Diseases. 2024;12(1). doi:10.1093/ofid/ofae705
BibTeX
@article{vanKampen2024,
author = {van Kampen, Jeroen J A and van Nood, Els and Mahmud, Rizwan and Krullaars, Zoë and Voskamp, Tess and Voskamp, Mike and Nijssen, Tess and Voermans, Jolanda J C and Charpentier, Charlotte and Le Hingrat, Quentin and van de Vijver, David A M C and Gruters, Rob A and Mesplède, Thibault},
title = {Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report},
journal = {Open Forum Infectious Diseases},
year = {2024},
volume = {12},
number = {1},
doi = {10.1093/ofid/ofae705}
}
EUVIMED